Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65‐75 years
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65‐75 years
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF HEMATOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-04-03
DOI
10.1002/ajh.25797
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of autologous stem cell transplantation in patients aged ≥ 65 years with multiple myeloma in the era of novel agents
- (2019) Shohei Mizuno et al. BONE MARROW TRANSPLANTATION
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
- (2019) Thierry Facon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Autologous stem cell transplant in older patients (age ≥ 65) with newly diagnosed multiple myeloma: A systematic review and meta-analysis
- (2019) Hira Mian et al. Journal of Geriatric Oncology
- Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies
- (2019) Michael A. Liu et al. BLOOD
- Real-word data on autologous stem cell transplantation in older patients with multiple myeloma
- (2019) Frida Schain et al. ANNALS OF HEMATOLOGY
- Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib
- (2018) Max J. Gordon et al. CANCER
- Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)
- (2018) Alessandra Larocca et al. LEUKEMIA
- Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
- (2018) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Real-life data on safety and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma
- (2018) Carolina Marini et al. ANNALS OF HEMATOLOGY
- Geriatric Assessment in Older Adults with Multiple Myeloma
- (2018) Tanya M. Wildes et al. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
- A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients
- (2017) Monika Engelhardt et al. HAEMATOLOGICA
- A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients
- (2017) Monika Engelhardt et al. HAEMATOLOGICA
- N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma
- (2016) Paolo Milani et al. AMERICAN JOURNAL OF HEMATOLOGY
- Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study
- (2016) Laurent Garderet et al. HAEMATOLOGICA
- Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores
- (2016) M. Engelhardt et al. HAEMATOLOGICA
- Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study
- (2016) Laurent Garderet et al. HAEMATOLOGICA
- Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores
- (2016) M. Engelhardt et al. HAEMATOLOGICA
- Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report
- (2015) A. Palumbo et al. BLOOD
- Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL study group
- (2015) Valentin Goede et al. LEUKEMIA & LYMPHOMA
- Survival of Multiple Myeloma Patients Aged 65-70 Years in the Era of Novel Agents and Autologous Stem Cell Transplantation
- (2014) Shuji Ozaki et al. ACTA HAEMATOLOGICA
- Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation
- (2014) Manish Sharma et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years
- (2014) H W Auner et al. BONE MARROW TRANSPLANTATION
- Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL)
- (2014) Alessandra Tucci et al. LEUKEMIA & LYMPHOMA
- Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents
- (2013) M. Merz et al. ANNALS OF ONCOLOGY
- Hematopoietic Cell Transplant Comorbidity Index Is Predictive of Survival after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma
- (2013) Ayman Saad et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results
- (2013) F. Gay et al. BLOOD
- A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy
- (2009) Alessandra Tucci et al. CANCER
- Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis
- (2008) Shaji K. Kumar et al. AMERICAN JOURNAL OF HEMATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started